QUEBEC CITY, January 26, 2012 - DiagnoCure, Inc. (TSX: CUR),
a life sciences company that develops and commercializes
high?value cancer diagnostic tests, today announced that its
partner for the PrevistageTM GCC Colorectal
Cancer Staging Test, Signal Genetics, reported the results of
a new study presented on January 21 at the 2012 American
Society of Clinical Oncology Gastrointestinal Cancer
Symposium held in San Francisco, CA. The poster entitled
"Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as
a Prognostic Marker in Patients with Stage II Colon Cancer: A
Pooled Analysis" confirms prognostic capabilities of the
Previstage test in patients with colon cancer.
Based on the pooled individual data analysis on 310 patients
and involving researchers and collaborators from several
centers, the study shows that the GCC levels allow an
effective stratification of patients between those that are
essentially cured and those at high risk of disease
recurrence. The 5?year recurrence risks were estimated at 11%
and 32% for the low and high risk groups respectively. Higher
detection levels of GCC in lymph nodes were also
significantly associated with increased risk of all?cause
mortality, disease?specific survival, and disease?free
survival.
Every year in the United States and Canada, 165,000 people
are diagnosed with colorectal cancer. Of that number, 69,000
are considered at low risk after their surgery. Yet, up to
20% of them suffer recurrence of a more advanced cancer.
PrevistageTM GCC is currently the only
colorectal cancer staging test on the market that provides
prognostic information based on the tumor burden measured at
the molecular level in the lymph nodes. Tumor burden in the
lymph nodes has become more widely recognized by treating
physicians as a key prognostic factor to determine the risk
of recurrence of cancer patients, and hence, to determine
which patients might benefit most from adjuvant chemotherapy
and which could be safely managed without chemotherapy.
To date, results of published studies totaling over 1,000
patients have shown that the GCC biomarker is a better
predictor, than traditionally?used factors, of disease
recurrence in early?stage colorectal cancer patients.
In particular, in a recent study (Annals of Surgical
Oncology, May 2011), in a sub?set of 181 stage II colon
cancer patients, the PrevistageTM GCC test
classified one?third of patients as having a high risk of
recurrence following surgery and two?thirds of patients at
low risk of recurrence. The high risk group had a six times
greater likelihood of recurrence than the low risk group (27%
versus 4%).
DiagnoCure (TSX: CUR) is a life sciences company that
develops and commercializes high?value cancer diagnostic
tests that increase clinician and patient confidence in
making critical treatment decisions. In 2008, the Company
launched the PrevistageTM GCC Colorectal Cancer
Staging Test through its U.S. CLIA laboratory, and granted
the worldwide exclusive rights to this test to Signal
Genetics in June 2011. The Company also has a strategic
alliance with Gen?Probe (NASDAQ: GPRO) for the development
and commercialization of a second?generation prostate cancer
test using PCA3, DiagnoCure's proprietary molecular
biomarker. The PROGENSA® PCA3 test is
commercialized in Europe under CE mark and was recently
approved in Canada; in the United States, the test is
commercialized through clinical laboratories using PCA3
analyte specific reagents from Gen?Probe; a PMA application
was filed with the FDA. For more information, visit www.diagnocure.com.
This release contains forward?looking statements that involve
known and unknown risks, uncertainties and assumptions that
may cause actual results to differ materially from those
expected. By their very nature, forward?looking statements
are based on expectations and hypotheses and also involve
risks and uncertainties, known and unknown, many of which are
beyond DiagnoCure's control. As a result, investors are
cautioned not to place undue reliance on these
forward?looking statements. The forward?looking statements
regarding the outcome of research and development projects,
clinical studies and future revenues are based on management
expectations. In addition, the reader is referred to the
applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the
heading "Risk Factors". DiagnoCure undertakes no obligation
to publicly update or revise any forward?looking statements
contained herein unless required by the applicable securities
laws and regulations.
?30?
Chief Financial Officer Coordinator, Administration and
Communications
(418) 527?6100 (418) 527?6100 communications@diagnocure.com communications@diagnocure.com
2
distribué par | Ce noodl a été diffusé par DiagnoCure Inc. et initialement mise en ligne sur le site http://www.diagnocure.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-26 14:07:53 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |
Documents associés | |
DiagnoCure announces publication of a meta-analysis on Previstage GCC Colorectal Cancer Test |